Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hoffmann-La Roche |
---|---|
Information provided by: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT00303485 |
This study will determine the rapidity of suppression of the bone resorption marker sCTX in post-menopausal women with osteoporosis.Other bone turnover markers will also be evaluated. Patients will be randomised to either monthly Boniva 150mg or placebo, in combination with vitamin D and calcium supplementation. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals.
Condition | Intervention | Phase |
---|---|---|
Post-Menopausal Osteoporosis |
Drug: ibandondronate [Bonviva/Boniva] Drug: Placebo Drug: Vitamin D and calcium supplementation |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized Double-Blind Study to Determine the Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once-Monthly Boniva (Ibandronate) Versus Placebo in the Treatment of Post-Menopausal Osteoporosis |
Enrollment: | 67 |
Study Completion Date: | July 2007 |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: ibandondronate [Bonviva/Boniva]
150mg po monthly for 6 months
Drug: Vitamin D and calcium supplementation
As prescribed
|
2: Placebo Comparator |
Drug: Placebo
po monthly for 6 months
Drug: Vitamin D and calcium supplementation
As prescribed
|
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
La Jolla, California, United States, 92037 | |
BEVERLY HILLS, California, United States, 90211 | |
United States, Georgia | |
AUGUSTA, Georgia, United States, 30904 | |
United States, Minnesota | |
WOODBURY, Minnesota, United States, 55125 | |
United States, New York | |
BRONX, New York, United States, 10461 | |
United States, Pennsylvania | |
HOPWOOD, Pennsylvania, United States, 15445 | |
United States, Wisconsin | |
MADISON, Wisconsin, United States, 53705 | |
Puerto Rico | |
SAN JUAN, Puerto Rico, 00935 | |
PONCE, Puerto Rico, 00717-1318 | |
SANTURCE, Puerto Rico, 00909 |
Study Director: | Clinical Trials | Hoffmann-La Roche, +1 973 235 5000 |
Responsible Party: | Hoffmann-La Roche ( Clinical Trials, Study Director ) |
Study ID Numbers: | ML19334 |
Study First Received: | March 16, 2006 |
Last Updated: | January 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00303485 |
Health Authority: | United States: Food and Drug Administration |
Calcium, Dietary Vitamin D Ibandronic acid Musculoskeletal Diseases Bone Resorption Ergocalciferols |
Osteoporosis, Postmenopausal Osteoporosis Bone Diseases, Metabolic Bone Diseases Menopause |
Physiological Effects of Drugs Bone Density Conservation Agents Pharmacologic Actions |